Abstracts abusers were 1.5-fold as likely to have medically related absenteeism days, and 8.5 times as likely to have a disability claim compared to controls (p < 0.01). Opioid abusers had higher average annual medically related absenteeism days compared to controls (26.4 days vs. 5.7 days, p < 0.01). Mean annual direct health care costs for opioid abusers were over eight times higher than controls ($15,884 vs. $1830, p < 0.01). Hospital inpatient and doctor/outpatient costs accounted for 46% ($7239) and 31% ($5000) of opioid abusers' health care costs, versus 17% ($310) and 50% ($906), respectively, for controls. Mean annual indirect workloss costs for opioid abusers were over eight times higher than controls ($4167 vs. $502, p < 0.01). CONCLU-SIONS: These high costs were driven partly by high utilization rates of medical services and prescription drugs, and higher prevalence of workloss. Our estimates may be conservative as only patients diagnosed with abuse were included. To the extent that the abuse is prescription opioid abuse, payers should ensure appropriate access to opioids while considering abuse liability of drugs on formulary. Charges were adjusted using a 0.55 cost-to-charge ratio. RESULTS: Of 1803 cases identified, 52% were male and 55% were less than 20-years old. Ambulances were used to transport 54%; law enforcement was involved in 1.5% of cases. The majority (69%) arrived between 10:00 PM and 4:00 AM, and 70% of all visits occurred Friday through Sunday. Significantly (p = 0.004) more visits occurred in September and October than any other month. The majority (94%) were treated and released from ED, 1% was hospitalized, 2% eloped or left AMA, 2% were transferred and 1% was recorded as unknown. Mean duration of ED visit was 5.4 hours (median: 4). Mean cost per ED visit was $482 (median: $382) for those treated and released, and $537 (median: $460) for those hospitalized. On average, those admitted (n = 20) spent 2.5 days (median: 1) in the hospital at a cost of $4540 (median: $2154). The cumulative hours of ED time used in one year for treating alcohol intoxication in this age group was 8254. Cumulative cost of ED and inpatient care for the year was roughly $938,000. Managed care organizations and commercial insurers were the responsible payers for most cases (60%). Self-pay was noted for 24%. CONCLU-SIONS: Acute alcohol intoxication among those of college age results in a substantial direct medical cost, as well as an opportunity cost for ED resources during the year, particularly at the start of the school year. 
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PMH3 QUALITY-ADJUSTED LIFE YEARS GAINED WITH BUPRENORPHINE TREATMENT FOR OPIATE ADDICTION

OBJECTIVES:
To determine quality-adjusted life-year (QALY) gains associated with buprenorphine treatment for opiate addiction, and estimate the potential cost savings of this treatment from the societal perspective. METHODS: In a randomized clinical trial of buprenorphine therapy, subjects completed the short-form-36 (SF-36) at baseline and every four weeks through week-16, creating up to five data collection points for each patient. We converted SF-36 data to SF-6D to calculate QALYs for each patient-month through published techniques based upon standard gamble methods. Dependent t-tests were used to identify significant differences in QALYs at baseline versus QALYs at the end of each month. Our base case used a buprenorphine 12 mg/day dosage plus annual buprenorphine treatment clinic costs ($2356/person). We incorporated social costs of untreated opiate addiction from the literature ($42,957/personyear) and performed a sensitivity analysis using 8 mg and 16 mg buprenorphine dosages. RESULTS: Due to dropouts, our sample size was 100, 80, 69, 59, and 44 patients at baseline and months one-four, respectively. QALY values (mean ± SD) for each month were: 0.734 ± 0.091 at baseline, 0.761 ± 0.068 at month-one, 0.751 ± 0.087 at month-two, 0.754 ± 0.087 at month-three, and 0.757 ± 0.090 at month-four. Thus, an improvement of 0.027 QALYs (P = 0.008) between baseline and month-one occurred (95% CI = 0.007-0.047). There were no other significant improvements, possibly due to patient dropouts. The sensitivity analysis showed direct medical costs for buprenorphine treatment ranged from $4206 to $6056 per person-year. By incorporating societal costs of untreated opiate addiction, a savings of $36,901 to $38,752 per person-year was estimated. CONCLU-SIONS: From a societal perspective, buprenorphine treatment saves money and increases QALYs. For every 37 (95%CI = 21-143) patients treated there is a gain of one QALY. Widespread adoption of proper office-based buprenorphine treatment is clearly indicated; undertreatment leads to exorbitant social costs without QALY gains.
MENTAL HEALTH-Anxiety PMH4 COST-EFFECTIVENESS OF ALPRAZOLAM IN ANXIETY DISORDERS
García-Contreras F, Castro-Ríos A, Nevarez-Sida A, Constantino-Casas P, Contreras-Hernández I, Mould J, Garduño-Espinosa J Mexican Institute of Social Security, Mexico City, Mexico OBJECTIVE: To estimate cost-effectiveness of Alprazolam versus Clonazepam, Fluoxetine and Imipramine in anxiety disorders in the Mexican Institute of Social Security (IMSS). METHODS: A cost-effectiveness study was carried out with a time horizon of one year, no discount rate was used. Utilization of resources and effectiveness data were taken from an expert panel of psychiatrists working at the IMSS and private sector. Inclusion criteria for experts were: psychiatrists with more than five years of clinical experience, that were certified by the Mexican Council of Psychiatry and that had experience in using the studied drugs in anxiety disorders. Use of resources included hospitalisation, emergency services, visits, laboratory and diagnostic tests, as well as pocket expenses. Unit costs were taken from Administrative and Financial departments of IMSS. Costs were expressed in 2004 USD. Effectiveness measure was days free of symptoms. Sensitivity analysis was univariate and probabilistic. RESULTS: Annual treatment cost of anxiety disorders with Alprazolam was $13,110, with Clonazepam $13,367, with Fluoxetine $13,423 and with Imipramine $14,803. Effectiveness results were 224 days without symptoms for Alprazolam, 232 for Clonazepam and 181 for Fluoxetine and Imipramine. The incremental cost-effectiveness analysis showed that the cost of an extra unit of effectiveness was $32.2 when changing from Alprazolam to Clonazepam, while the two other alternatives (Fluoxetine and Imipramine) were dominated. Sensitivity analysis confirmed the direction and strength of our results. Confidence interval at 95% of the ICER was calculated by the ellipse method and it showed that Alprazolam was dominant in 87% of the cases. Acceptability curve described Alprazolam as the best option with a willingness to pay threshold of $32.2. CONCLU-SIONS: The best cost-effective alternative was Alprazolam followed by Clonazepam. This results are relevant for the IMSS because anxiety disorders cause work leaves and hospitalisations, and reduction in quality of life.
PMH5 ECONOMIC BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) AND OTHER ANXIETY DISORDERS
Medstat, Washington, DC, USA; 2 Pfizer, Inc, New York, NY, USA OBJECTIVES: To assess the health and cost burdens of patients with generalized anxiety disorder (GAD) and other anxiety disorders, including their comorbidities, direct and indirect costs.
METHODS: The 1999-2003 MarketScan
® claims databases of over three million individuals (annually) were used to identify patients with a diagnosis of GAD, other anxiety disorders (panic disorder, phobias, post traumatic stress disorder, unspecified anxiety state), and demographically-matched controls. Presence of comorbidities, utilization, expenditures, absence and shortterm disability (STD) were summarized over a 12-month study period. RESULTS: The prevalence of the following conditions were significantly (p < 0.001) higher among the 13,836 GAD subjects and 31,882 other anxiety patients compared to the 89,971 controls: gastrointestinal disorders (19% GAD, 22% other anxiety, 12% controls), genitourinary disorders (40% GAD and other anxiety, 32% controls), cardiovascular disease (10% GAD, 11% other anxiety, 7% controls), and chronic pain (40% GAD, 44% other anxiety, 20% controls). Mean costs for anxiety patients were twice as high as for controls ($6295 GAD, $6800 other anxiety, $3156 controls, p < 0.001). These differences were driven by significantly higher rates of office visits and prescription drug use among anxiety patients. Mental health costs for GAD patients ($2031) or other anxiety patients ($2005) did not account for all of the discrepancy. Among the subset of patients with productivity data, anxiety patients had significantly higher indirect costs due to STD days ($2253 GAD, $3255 other anxiety, $934 controls, p < 0.001). CONCLUSION: Patients with GAD and other anxiety disorders have significantly higher costs compared to patients without these conditions. The direct and indirect costs of anxiety result from mental health treatment and treatments for physical comorbidities.
PMH6 DETERMINANTS OF PERMANENT NUSRING HOME ADMISSIONS AMONG ELDERLY IN THE UNITED STATES
Cai QC, Lin SJ University of Illinois, Chicago, IL, USA OBJECTIVES: To examine the determinants of time-topermanent nursing home admission among people aged 65 years and over in the United States. METHODS: This study used data from four waves of the Health Retirement Study (HRS) and Assets and Health Dynamics among the Oldest Old surveys (AHEAD) collected from 1995 to 2002. The dependent variable was time-to-permanent nursing home admission, defined as the months from baseline survey in 1995 to the first nursing home stay of three or more months. Independent variables were measured at the baseline and included age, gender, race, education, marital status, living arrangements, income, homeownership, Medicaid, physical function (ADL/IADL), cognitive level, perceived health status and certain chronic illnesses such as stroke, psychiatric problems, fall and incontinence. RESULTS: In the final multivariable Cox model, older age (Hazard Ratio [HR], 1.11; 95% CI, 1.09-1.24), persons with psychiatric problems (HR, 1.49; 95% CI, 1.19-1.87) and worse health were found to increase the risk of permanent nursing home admission whereas being African American compared to white (HR, 0.85; 95% CI, ) and persons with less cognitive impairment (HR, 0.95; 95% CI, 0.91-0.99) had decreased risk. The interaction terms between time and living alone and IADL were significant and less than one, which means the negative impacts of living alone and worse IADL were decreasing over time. Gender, education, marital status, income, homeownership, Medicaid, ADL, stroke, fall and incontinence were not significant. CONCLUSION: Older age, psychiatric problems and worse perceived health are the risk factors for permanent nursing home admission. Living alone and worse IADL also increase the risk of nursing home admission, however, the negative impacts appear to ameliorate over time. The differential effects of ADL and IADL on nursing home admission warrant more future research.
PMH7 THE EFFECT OF VENLAFAXINE, PAROXETINE, AND PLACEBO ON HEALTH-RELATED WORK PRODUCTIVITY IN PANIC DISORDER PATIENTS
Khandker R, Zhang HF Wyeth Research, Collegeville, PA, USA OBJECTIVES: This study assessed the effect of treatment with venlafaxine extended release (XR), paroxetine and placebo on health related work productivity among panic disorder patients. METHODS: In a multicenter, double-blind trial, patients with DSM-IV panic disorder were randomly assigned to fixed-dose (75 mg/day or 225 mg/day) venlafaxine XR, paroxetine (40 mg/day), or placebo for a maximum of 12-weeks. Secondary analyses focused on health-related work productivity impairments as measured by the Work Limitations Questionnaire (WLQ). WLQ has 25 items in four limitation dimensions (time, physical, mental-interpersonal, and output demands). Treatment-related improvements at final-on-therapy (FOT) and week 12 were compared using analysis of covariance adjusting for baseline impairment score and center. RESULTS: Venlafaxine XR 225 mg was associated with significantly greater improvement from baseline, relative to placebo, on all subscales of WLQ (P < 0.005) except physical demands. At the FOT assessment, venlafaxine XR 75 mg showed significant improvement compared with placebo in time management (P < 0.05), marginally significant improvement in mental/interpersonal demands (P = 0.059) and output demands (P = 0.054), and no significance for physical demands. Paroxetine failed to show significant improvement relative to placebo on all WLQ subscales in the FOT assessment. CONCLUSION: Venlafaxine reduced work impairment compared to placebo. Paroxetine did not separate from placebo. 
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